Drug intelligence / Profile preview

ketotifen + naphazoline

Development stage
Unknown
Lead developer
Bausch & Lomb
Modality
Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Ketotifen + naphazoline is a fixed-dose combination ophthalmic drug used primarily for the symptomatic relief of allergic conjunctivitis and related ocular conditions. Ketotifen acts as a noncompetitive histamine H1 receptor antagonist and mast cell stabilizer, reducing allergic inflammation by blocking histamine-mediated symptoms and preventing the release of inflammatory mediators from mast cells. Naphazoline is an imidazoline-derived sympathomimetic vasoconstrictor that acts as an alpha adrenergic receptor agonist, leading to constriction of conjunctival blood vessels, thereby reducing eye redness and congestion. The combination provides both rapid relief from redness (via vasoconstriction) and longer-term control of itching (via antihistaminic/mast cell stabilization). It is typically administered as eye drops for short-term use in allergic or irritative conjunctivitis[1][3][4][5].

Other names
ketotifen + naphazoline
02

Targets

ADRA1 (Alpha-1 adrenergic receptor family)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on ketotifen + naphazoline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketotifen + naphazoline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call